Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2006

01-08-2006 | Review Article

Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension

A Systematic Review of Economic Evidence

Authors: Dr Michelle Orme, Annabel Boler

Published in: PharmacoEconomics | Issue 8/2006

Login to get access

Abstract

We conducted a systematic review of economic studies of prostaglandin analogues for the treatment of glaucoma to assess the scope of current cost-effectiveness evidence and its relevance to decision-makers. The literature search retrieved 102 studies published before July 2005; after additional hand searching of conference proceedings, 13 full-text articles and 13 abstracts met the inclusion criteria. The reviewers extracted the key characteristics of each of the economic evaluations, and all studies received a grade in five categories to summarise the quality of the study: methodology, transparency, sensitivity, relevance and overall score.
The current economic literature is predominantly focused on identifying the short-term direct cost of glaucoma treatment, particularly the precise quantification of glaucoma drug costs. Using the European and US treatment guidelines as a benchmark, it is evident that the current body of literature does not satisfy the needs of decision-makers, although certain studies provide some valuable information, which is a step towards reaching this goal.
The main methodological issue in the economic models is an absence of a clinically relevant long-term effectiveness measure, or where this measure is produced, there is a lack of transparency and validation of the methods used. More attention needs to be given to modelling the consequences of treatment, and those consequences should include patient compliance, control of intraocular pressure and progression of visual field deficit, since these drive both the costs and the overall outcomes.
We recognise that constructing the ‘ideal’ clinical outcome measure represents a major challenge to researchers. As such, we have outlined a modelling framework that could be used to produce the required level of economic evidence, and ongoing clinical research (such as the Early Manifest Glaucoma Trial) could provide the validated link between intraocular pressure and disease progression, which forms an essential part of such models.
Appendix
Available only for authorised users
Footnotes
1
The search strategies used to search the databases are in the supplementary material to this article, which is listed as ‘ArticlePlus’ and can be found with the electronic version of this article on AdisOnline (www.AdisOnline.com/phe).
 
2
A table outlining key characteristics and top-line results for each of the included evaluations is in the supplementary material to this article, which is listed as ‘ArticlePlus’ and can be found with the electronic version of this article on AdisOnline (www.AdisOnline.com/phe).
 
Literature
1.
World Health Organization. Magnitude and causes of visual impairment: fact sheet no. 282. 2004 Nov [online]. Available from URL: http://​www.​who.​int/​mediacentre/​factsheets/​fs282/​en/​index.​html [Accessed 2005 Jul]
2.
European Glaucoma Society. Terminology and guidelines for glaucoma. 2nd ed. Savona, Italy: Dogma srl, 2003
3.
Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers’ handbook. Annex C: methodology checklist 6. Economic evaluations [online]. Available from URL: http://​www.​sign.​ac.​uk/​guidelines/​fulltext/​50/​annexc.​html [Accessed 2005 May]
4.
American Academy of Ophthalmology Preferred Practice Patterns Glaucoma Panel. Preferred practice pattern: primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2003
5.
Aballea S, Martin M, Bernard L, et al. Economic evaluation of latanoprost as first line glaucoma therapy in 6 European countries [abstract]. Value Health 2003; 6 (3): 639CrossRef
6.
Bernard LM, Althin R, Dhawan R, et al. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 2003; 13 Suppl. 4: S3043
7.
Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004; 20 (5): 383–92PubMedCrossRef
8.
Doyle J, Casciano J, Walt J, et al. Cost-effectiveness of bimatoprost 0.03% versus a combination product of timolol 0.5% and dorzolamide 2.0% for glaucoma [abstract]. Value Health 2003; 6 (3): 238CrossRef
9.
Evans S, Doyle J, Casciano J, et al. Prostamines vs combination products for glaucoma treatment: effectiveness and cost considerations [abstract]. Value Health 2001; 4 (6): 515CrossRef
10.
Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136 (1), 18–25PubMedCrossRef
11.
Gosden T, Costello S, Orme ME, et al. Cost-effectiveness of latanoprost in first line treatment of primary open angle glaucoma in the UK [abstract]. Value Health 2004; 7 (6): 747CrossRef
12.
Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 2002; 100: 109–17PubMed
13.
Ikeda H, Sato E, Kitaura T, et al. Daily cost of ophthalmic solutions for treating glaucoma in Japan. Jpn J Ophthalmol 2001; 45 (1): 99–102PubMedCrossRef
14.
Kobelt G, Jonsson L, Gerdtham U, et al. Direct costs of glaucoma management following initiation of medical therapy: a simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998; 236 (11): 811–21PubMedCrossRef
15.
Kobelt G, Jonsson L. Modeling cost of treatment with new topical treatments for glaucoma: results from France and the United Kingdom. Int J Technol Assess Health Care 1999; 15 (1), 207–19PubMedCrossRef
16.
Le Pen C, Ligier M, Berdeaux G. Cost-effectiveness and costutility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom. J Med Econ 2005; 8: 67–84CrossRef
17.
Malone D, Ward S, Gesser K. A cost-effectiveness analysis treating open angle glaucoma [abstract]. Value Health 2004; 7 (3), 259CrossRef
18.
Mick AB, Gonzalez S, Dunbar MT, et al. A cost analysis of the prostaglandin analogs. Optometry 2002; 73 (10): 614–9PubMed
19.
Poulsen P, Christensen T, Holmstrom S, et al. Model-based comparative pharmacoeconomic analyses of bimatoprost 0.3% in the treatment of glaucoma or ocular hypertension in adult patients in Austria and Finland [abstract]. Value Health 2003; 6 (3), 239CrossRef
20.
Reardon G, Sheffield RE, Schwartz GF, et al. Cost-effectiveness of ocular prostaglandins in the first year using persistency on therapy to define treatment success [abstract]. Annual Meeting, Association for Research in Vision and Ophthalmology; 2005 May 1–5; Fort Lauderdale (FL)
21.
Roberts G, Buchholz P, Holstom S, et al. Comparison of the clinical efficacy and cost-effectiveness of lumigan and xalatan in the treatment of glaucoma [abstract]. Value Health 2003; 6 (3), 639CrossRef
22.
Rouland JF, Le Pen C, Ophthalmologists of the Glaucoma Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 2003; 13 Suppl. 4: S5–20PubMed
23.
Soto J, De Miguel V. A cost-effectiveness analysis of latanoprost in the treatment of open angle glaucoma in Spain [abstract]. Value Health 2004; 7 (6): 746CrossRef
24.
Soto J, De Miguel V. A pharmacoeconomic analysis of the fixed combination latanoprost/timolol versus dorzolamide/timolol in the treatment of patients with glaucoma in Spain [abstract]. Value Health 2004; 7 (6): 747CrossRef
25.
Stewart WC, Leech J, Sharpe ED, et al. An economic analysis of switching to latanoprost from a beta-blocker or ackling brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Manag Care 2002; 8(10 Suppl.): S240–8PubMed
26.
Vetrugno M, Christensen T, Poulsen PB, et al. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% (lumigan) in the treatment of glaucoma or ocular hypertension as alternative to filtration surgery in Italy [abstract]. Value Health 2003; 6 (6): 628CrossRef
27.
Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 2002; 11 (4): 354–8PubMedCrossRef
28.
Walt JH, Spalding JR, Habib L. Cost-effectiveness of bimatoprost versus latanoprost plus adjunctive products for glaucoma treatment [abstract]. Value Health 2003; 6 (3): 237CrossRef
29.
Walt JG, Lee IT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49 Suppl. 1: S36–44PubMedCrossRef
30.
Walt JG, Chiang TH, Guckian A, et al. Refill costs and budget impact of glaucoma lipid therapy: a retrospective database analysis [abstract]. Value Health 2005; 8 (3): 368CrossRef
31.
Serle J, Cantor L, Gross R. Best practice treatment algorithm for primary open-angle glaucoma: implications for US ophthalmology practice. Manag Care Interface 2002; 15: 37–48PubMed
32.
Stewart WC, Chorac RP, Hunt HR, et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116: 176–81PubMed
33.
Nordmann JP, Auzanneau N, Ricard S, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 2003 Dec 10; 1 (1): 75PubMedCrossRef
34.
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–79PubMed
35.
Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121 (1): 48–56PubMedCrossRef
Metadata
Title
Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension
A Systematic Review of Economic Evidence
Authors
Dr Michelle Orme
Annabel Boler
Publication date
01-08-2006
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2006
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624080-00002

Other articles of this Issue 8/2006

PharmacoEconomics 8/2006 Go to the issue

Original Research Article

A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction

Original Research Article

Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada

Correspondence

National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget

Original Research Article

Costs of Inflammatory Bowel Disease in Germany

Original Research Article

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease

Review Article

Cost Effectiveness of Leukotriene Modifiers in Adults with Asthma